Please assess the completion status of the following clinical trial:

Trial Title: KPL-301 for Subjects With Giant Cell Arteritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Selected Inclusion Criteria:~1. Subjects with new-onset or relapsing/refractory GCA.~2. Westergren erythrocyte sedimentation rate \> 30 mm/hour or c-reactive protein ≥ 1 mg/ dL.~3. Remission of GCA at or before Day 0.~4. Female subjects must be postmenopausal or permanently sterile following documented hysterectomy, bilateral salpingectomy, bilateral oophorectomy, or tubal ligation or having a male partner with vasectomy as affirmed by the subject, or nonpregnant, nonlactating, and if sexually active having agreed to use a highly effective method of contraception.~5. Male subjects must have documented vasectomy or if sexually active must agree to use a highly effective method of contraception with their partners of childbearing potential.~Selected Exclusion Criteria:~1. Transplanted organs (except corneal transplant performed more than 3 months prior to randomization).~2. Concurrent enrollment in another interventional clinical study.~3. Treatment with non-biologic investigational drug therapy within 4 weeks or 5 half-lives of the study agent, whichever was longer, prior to screening.~4. Cell-depleting biological therapies within 12 months prior to Day 0, or noncell-depleting biological therapies within 8 weeks (or 5 half-lives, whichever is longer) prior to screening.~5. Treatment with alkylating agents within 12 weeks prior to screening.~6. Intramuscular, Intra-articular or IV corticosteroids within 4 weeks prior to screening.~7. Receipt of live (attenuated) vaccine within the 4 weeks before Day 0.~8. Treatment with hydroxychloroquine, cyclosporine A, azathioprine, cyclophosphamide, or mycophenolate mofetil (MMF) within 4 weeks of screening.~9. Female subjects who are pregnant, intending to become pregnant, or are breastfeeding.~10. Known history of allergy or reaction to any component of the mavrilimumab or placebo formulation or to any other biologic therapy or prednisone or any of its excipients.~11. Positive (or 2 indeterminate) QuantiFERON test results.~12. Clinically significant active infection or infection requiring hospitalization or IV antibiotics within 12 weeks before screening or opportunistic infection within 6 months before screening.~13. Chronic active hepatitis B infection.~14. Subjects at a high risk of infection, a history of an infected joint prosthesis still in situ, leg ulcers, indwelling urinary catheter, or persistent or recurrent chest infections.~15. History of cancer within the last 10 years, except for basal and squamous cell carcinoma of the skin or in situ carcinoma of the cervix treated and considered cured.~16. Evidence of clinically-uncontrolled respiratory disease.~17. History of chronic respiratory tract infections.

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- mavrilimumab (Type: ACTIVE_COMPARATOR): Subjects randomized to mavrilimumab will receive 150 mg every other week by subcutaneous injection co-administered with a 26-week corticosteroid taper.
- placebo (Type: PLACEBO_COMPARATOR): Subjects randomized to placebo will receive placebo every other week by subcutaneous injection co-administered with a 26-week corticosteroid taper.

Based on this trial design, predict the completion outcome and termination type (if applicable).